Prostate Cancer - Results from #1860

CONFIRM trial Protocol: The utility of PSMA PET/CT in active surveillance for prostate cancer. November 1, 2023

Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. November 1, 2023

Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors. November 1, 2023

Racial disparity in the utilization of immunotherapy for advanced prostate cancer. November 1, 2023

ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer. November 1, 2023

Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer: Three Year Outcomes from a Prospective Trial. October 31, 2023

Making the Case for Autophagy Inhibition as a Therapeutic Strategy in Combination with Androgen-Targeted Therapies in Prostate Cancer. October 31, 2023

EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer. October 31, 2023

Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer. October 30, 2023

Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial. October 30, 2023

Deep learning-based ultrasound auto-segmentation of the prostate with brachytherapy implanted needles. October 30, 2023

TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. October 30, 2023

Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy. October 30, 2023

Diagnostic accuracy of fully hybrid [68Ga]Ga-PSMA-11 PET/MRI and [68Ga]Ga-RM2 PET/MRI in patients with biochemically recurrent prostate cancer: a prospective single-center phase II clinical trial. October 30, 2023

Clarity and PSI Kick Off SAR-bisPSMA Phase III October 27, 2023

Novartis Confirms Unconstrained Supply for Pluvicto® and Continues to Significantly Expand the Number of Treatment Centers October 27, 2023

Robot-Assisted Surgery and Racial and Ethnic Disparities in Post-Prostatectomy Outcomes Among Prostate Cancer Patients. October 27, 2023

Disease control outcomes of stereotactic body radiation therapy or moderate hypo-fractionation for prostate cancer: Real-world experience at two Canadian centers. October 27, 2023

Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer-Combination Strategies. October 27, 2023

Pelvic irradiation for node-positive prostate cancer after prostatectomy: Long-term results of the prospective PLATIN-4 and PLATIN-5 trials. October 27, 2023

Page 94 of 1435